- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies
Nicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Nicole Concin, MD, professor, experimental gynecology, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
The phase 2 portion of the LIO-1 trial will enroll approximately 161 patients with advanced, recurrent, or metastatic gynecological malignancies, Concin says.
Four cohorts will be included in the study: endometrial cancer, cervical cancer, ovarian cancer excluding clear-cell histology, and clear-cell ovarian/endometrial cancer.
Clear-cell gynecologic carcinoma is a rare disease, so the inclusion of this subtype is a unique feature of the study, explains Concin.
The LIO-1 trial will evaluate the safety and efficacy of the investigational TKI lucitanib and nivolumab (Opdivo) in this patient population.
Related Content:
